Abstract
Ventilation is one of the most critical components in a layered approach toward reducing the spread of airborne infectious diseases in indoor spaces. However, building ventilation systems act together with natural ventilation, local filtration systems and other aerosol removal processes to remove infectious aerosols from an occupied space. Airflow-based determinations of ACH do not account for the full range of aerosol removal processes; however understanding the effective aerosol removal rate is critical to providing airborne infection control.
In this study, we investigated the relationship between the calculated air change rate of a space (i.e. volumetric airflow based) and the effective air change rate for aerosol particle removal within the breathing zone based on direct measurements of the rate of change in tracer particle concentrations at representative occupant locations in a room. Further, we examined positional effects under well mixed and non-well mixed conditions.
Our results demonstrate that tracer particles combined with real-time sensors can be used to make rapid, accurate measurements of the effective air change rate (eACH) for respiratory aerosols within the breathing zone of non-well mixed rooms. We used two experimental test beds for these analyses. First, numerical simulation (computational fluid dynamic simulation, CFD) was conducted to visualize airflow and particle removal paths within a realistic large room. Here, simulated sensors were placed in concentric zones around a nebulizer providing test-particle releases. This CFD model allowed a direct comparison of the differences between eACH and airflow ACH values under varying levels of mixing and airflow, in a fully controlled system.
We then recapitulated this system in physical space to validate the CFD results under real-world conditions that include all mechanisms of particle removal that contribute to true aerosol clearance rates, including deposition and leakage. Here, we measured eACH using the decay of DNA tracer aerosols nebulized and monitored in real-time. We find that a standard sampling time of 15 minutes from the end of nebulization is sufficient to produce an accurate eACH value under non-well mixed conditions. The availability of a rapid direct test for eACH will enable empirical optimization of a wide range of ventilation and filtration mechanisms to reach and maintain target aerosol clearance rates that deliver reliable airborne infection control in typical indoor environments.
Competing Interest Statement
This study was funded by Poppy Health, Inc. through Aerosol Research and Engineering Laboratories, Inc. (ARE Labs). ARE Labs has no affiliations with, or involvement in any capacity, with Poppy's financial interests such as membership, employment, stock ownership, or other equity interest.
Funding Statement
This study was funded by Poppy Health, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
FDA Compliance:This study was conducted in compliance with FDA Good Laboratory Practices (GLP) as defined in 21 CFR, Part 58.
Conflict of Interest: Aerosol Research and Engineering Laboratories, Inc. has no affiliations with, or involvement in any capacity, with Poppy’s financial interests such as membership, employment, stock ownership, or other equity interest.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
